CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease
Open Access
- 17 February 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (2), e339
- https://doi.org/10.1002/ctm2.339
Abstract
Inflammatory bowel disease (IBD) has emerged a global disease and the ascending incidence and prevalence is accompanied by elevated morbidity, mortality, and substantial healthcare system costs. However, the current typical one‐size‐fits‐all therapeutic approach is suboptimal for a substantial proportion of patients due to the variability in the course of IBD and a considerable number of patients do not have positive response to the clinically approved drugs, so there is still a great, unmet demand for novel alternative therapeutic approaches. Spleen tyrosine kinase (Syk), a cytoplasmic nonreceptor protein tyrosine kinase, plays crucial roles in signal transduction and there are emerging data implicating that Syk participates in pathogenesis of several gut disorders, such as IBD. In this study, we observed the Syk expression in IBD patients and explored the effects of therapeutic Syk inhibition using small‐molecule Syk inhibitor piceatannol in bone marrow–derived macrophages (BMDMs). In addition, due to the poor bioavailability and pharmacokinetics of small‐molecule tyrosine kinase inhibitors and superiority of targeting nanoparticles‐based drug delivery system, we herein prepared piceatannol‐encapsulated poly(lactic‐co‐glycolic acid) nanoparticles that conjugated with chemokine C–C motif ligand 4 (P‐NPs‐C) and studied its therapeutic effects in vitro in BMDMs and in vivo in experimental colitis model. Our results indicated that in addition to alleviating colitis, oral administration of P‐NPs‐C promoted the restoration of intestinal barrier function and improved intestinal microflora dysbiosis, which represents a promising treatment for IBD.Keywords
Funding Information
- National Natural Science Foundation of China (82072149)
This publication has 47 references indexed in Scilit:
- Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative ColitisInflammatory Bowel Diseases, 2016
- Regulation of chronic inflammatory and immune processes by extracellular vesiclesJCI Insight, 2016
- Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissueNanomedicine: Nanotechnology, Biology and Medicine, 2015
- Variability in bioavailability of small molecular tyrosine kinase inhibitorsCancer Treatment Reviews, 2015
- Getting Syk: spleen tyrosine kinase as a therapeutic targetTrends in Pharmacological Sciences, 2014
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- Endocytosis of nanomedicinesJournal of Controlled Release, 2010
- Interfacial Activity Assisted Surface Functionalization: A Novel Approach To Incorporate Maleimide Functional Groups and cRGD Peptide on Polymeric Nanoparticles for Targeted Drug DeliveryMolecular Pharmaceutics, 2010
- The SYK tyrosine kinase: a crucial player in diverse biological functionsNature Reviews Immunology, 2010
- Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17Nature Immunology, 2007